BACKGROUND:CF101, an adenosine A3 receptor agonist, is an orally bioavailable small molecule drug presenting an anti-psoriatic effect demonstrated in a Phase 2 clinical trial in psoriasis patients.<BR /> OBJECTIVE: To evaluate the safety and efficacy of CF101 treatment in a Phase 2/3 study in patients with moderate to severe plaque-type psoriasis.<BR />; METHODS: This multicenter, double-blind, 2-segment, placebo-controlled study randomized subjects with moderate to severe plaque psoriasis to CF101 1 or 2 mg, orplacebo twice daily. At either week 12 (Segment 1) or 16 (Segment 2), the placebo group crossed over to CF101 BID through week 32 in an open-label fashion. At week 12, following an interim analysis, the CF101 1mg group was discontinued due to futility. The primary endpoint was proportion of patients achieving ≥75% improvement in Psoriasis Area Severity Index (PASI 75). Efficacy testing was performed using the Cochran-Mantel Haenszel test, the primary analysis of PASI 75 was performed at the 0.035 significance level.<BR /> RESULTS:CF101 had an excellent safety profile at all tested dosages with a profile similar to the placebo group. The most common adverse events were infections and gastrointestinal events, and there was no cumulative intolerance over the 32-week dosing period. The study did not meet the primary endpoint of PASI 75 at week 12 (2 mg: 8.5% vs. placebo: 6.9%, <em>P</em>=0.621). However, at week 32, PASI mean percent improvement with CF101 2 mg was 57% (<EM>P</EM><0.001) compared to baseline, with linear improvement in PASI 50 (63.5%), 75 (35.5%), 90 (24.7%), and 100 (10.6%).<BR /> CONCLUSIONS: Oral CF101 was found to be safe and very well tolerated, demonstrating evidence of efficacy in patients with moderate to severe plaque psoriasis through 32 weeks of treatment.<BR /><BR /> <em>J Drugs Dermatol</em>. 2016;15(8):931-938.
RCT Entities:
BACKGROUND: CF101, an adenosine A3 receptor agonist, is an orally bioavailable small molecule drug presenting an anti-psoriatic effect demonstrated in a Phase 2 clinical trial in psoriasispatients.<BR /> OBJECTIVE: To evaluate the safety and efficacy of CF101 treatment in a Phase 2/3 study in patients with moderate to severe plaque-type psoriasis.<BR /> METHODS: This multicenter, double-blind, 2-segment, placebo-controlled study randomized subjects with moderate to severe plaque psoriasis to CF101 1 or 2 mg, or placebo twice daily. At either week 12 (Segment 1) or 16 (Segment 2), the placebo group crossed over to CF101 BID through week 32 in an open-label fashion. At week 12, following an interim analysis, the CF101 1mg group was discontinued due to futility. The primary endpoint was proportion of patients achieving &ge;75% improvement in Psoriasis Area Severity Index (PASI 75). Efficacy testing was performed using the Cochran-Mantel Haenszel test, the primary analysis of PASI 75 was performed at the 0.035 significance level.<BR /> RESULTS: CF101 had an excellent safety profile at all tested dosages with a profile similar to the placebo group. The most common adverse events were infections and gastrointestinal events, and there was no cumulative intolerance over the 32-week dosing period. The study did not meet the primary endpoint of PASI 75 at week 12 (2 mg: 8.5% vs. placebo: 6.9%, <em>P</em>=0.621). However, at week 32, PASI mean percent improvement with CF101 2 mg was 57% (<EM>P</EM>&LT;0.001) compared to baseline, with linear improvement in PASI 50 (63.5%), 75 (35.5%), 90 (24.7%), and 100 (10.6%).<BR /> CONCLUSIONS: Oral CF101 was found to be safe and very well tolerated, demonstrating evidence of efficacy in patients with moderate to severe plaque psoriasis through 32 weeks of treatment.<BR /><BR /> <em>J Drugs Dermatol</em>. 2016;15(8):931-938.
Authors: Courtney L Fisher; Lucas B Fallot; Tina C Wan; Robert F Keyes; R Rama Suresh; Amy C Rothwell; Zhan-Guo Gao; John D McCorvy; Brian C Smith; Kenneth A Jacobson; John A Auchampach Journal: ACS Pharmacol Transl Sci Date: 2022-07-15
Authors: Marc López-Cano; Ingrid Filgaira; Ernest G Nolen; Gisela Cabré; Jordi Hernando; Dilip K Tosh; Kenneth A Jacobson; Concepció Soler; Francisco Ciruela Journal: Pharmacol Res Date: 2021-06-19 Impact factor: 10.334
Authors: Elena Lucarini; Elisabetta Coppi; Laura Micheli; Carmen Parisio; Alessia Vona; Federica Cherchi; Anna M Pugliese; Felicita Pedata; Paola Failli; Seph Palomino; Jared Wahl; Tally M Largent-Milnes; Todd W Vanderah; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini; Carla Ghelardini; Lorenzo Di Cesare Mannelli Journal: Pain Date: 2020-09-01 Impact factor: 7.926